Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes
about
The links between insulin resistance, diabetes, and cancerEffect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2A benchmark data set for model-based glycemic control in critical careDose-response effects of insulin glargine in type 2 diabetes.Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes.Basal insulin treatment in type 2 diabetes.Management of progressive type 2 diabetes: role of insulin therapy.Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.Will the next generation of basal insulins offer clinical advantages?Euglycaemic glucose clamp: what it can and cannot do, and how to do it.Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES.Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial
P2860
Q26852910-DA0B79B7-52D2-4102-B767-176A41CE61EDQ28728738-56888281-8772-4A88-AE7E-EB98A0AA21AEQ33514624-84796B68-F469-428A-9212-B9923B335941Q33932753-FAC81EA9-1B1E-47A2-BD10-0610E057E5D6Q34613075-D8D3CC0E-C63D-4673-8EE9-12195DFCB6B7Q34620736-6CCC4009-DA3A-4266-A5C4-2C28DA8C1F8AQ36417426-5F5847E9-C137-445F-9754-5D1EDC144071Q37276717-C7891579-17A2-46B0-A836-DCF6CA5A7B35Q37636162-F58E5BC7-254F-4807-AD5F-ECEB01B300E2Q37771436-C47746BA-9A87-4DA5-8CDE-DC762F3FF592Q37853658-38A18283-13F1-4E18-84D0-175EA9C1578EQ38028009-A27EAC64-47DB-446A-9EC3-7A130D0081C8Q38151948-4595A336-FA09-44FD-8AAF-6E444BDCCFE3Q38871135-0F67CC83-3072-41F1-A1F2-91F3F53065F1Q39987991-F3D6CC04-1948-4933-8C2E-ECD94A7B2C4EQ51275520-4A47A012-42EB-4229-AACA-AB95F9C9E567Q58775144-2B9AA55D-EB7C-4A97-98E7-419A4CD8726A
P2860
Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes
description
im April 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 05 April 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2006
@uk
name
Comparison of the pharmacokine ...... in people with type 2 diabetes
@en
Comparison of the pharmacokine ...... in people with type 2 diabetes
@nl
type
label
Comparison of the pharmacokine ...... in people with type 2 diabetes
@en
Comparison of the pharmacokine ...... in people with type 2 diabetes
@nl
prefLabel
Comparison of the pharmacokine ...... in people with type 2 diabetes
@en
Comparison of the pharmacokine ...... in people with type 2 diabetes
@nl
P2093
P1433
P1476
Comparison of the pharmacokine ...... in people with type 2 diabetes
@en
P2093
P2888
P304
P356
10.1007/S00125-006-0243-2
P577
2006-04-05T00:00:00Z